Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3)
dc.contributor.author | Qaseem, Amir | |
dc.contributor.author | Yost, Jennifer | |
dc.contributor.author | Etxeandia-Ikobaltzeta, Itziar | |
dc.contributor.author | Abraham, George M | |
dc.contributor.author | Jokela, Janet A. | |
dc.contributor.author | Forciea, Mary Ann | |
dc.contributor.author | Miller, Matthew C. | |
dc.contributor.author | Humphrey, Linda L. | |
dc.date | 2022-08-11T08:08:11.000 | |
dc.date.accessioned | 2022-08-23T15:45:31Z | |
dc.date.available | 2022-08-23T15:45:31Z | |
dc.date.issued | 2022-03-01 | |
dc.date.submitted | 2022-03-16 | |
dc.identifier.citation | <p>Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL; Scientific Medical Policy Committee of the American College of Physicians*. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3). Ann Intern Med. 2022 Mar 1. doi: 10.7326/M21-4810. Epub ahead of print. PMID: 35226518. <a href="https://doi.org/10.7326/M21-4810">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 0003-4819 (Linking) | |
dc.identifier.doi | 10.7326/M21-4810 | |
dc.identifier.pmid | 35226518 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/27546 | |
dc.description.abstract | This is an update of the American College of Physicians' living, rapid practice points on the use of remdesivir for treatment of COVID-19. This update is based on an updated living, rapid systematic review that included studies published through 19 October 2021 and identified 2 new studies meeting inclusion criteria. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=35226518&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.relation.url | https://doi.org/10.7326/m21-4810 | |
dc.subject | remdesivir | |
dc.subject | COVID-19 | |
dc.subject | Health Services Administration | |
dc.subject | Health Services Research | |
dc.subject | Infectious Disease | |
dc.subject | Therapeutics | |
dc.subject | Virus Diseases | |
dc.title | Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3) | |
dc.type | Journal Article | |
dc.source.journaltitle | Annals of internal medicine | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/covid19/348 | |
dc.identifier.contextkey | 28374448 | |
html.description.abstract | <p>This is an update of the American College of Physicians' living, rapid practice points on the use of remdesivir for treatment of COVID-19. This update is based on an updated living, rapid systematic review that included studies published through 19 October 2021 and identified 2 new studies meeting inclusion criteria.</p> | |
dc.identifier.submissionpath | covid19/348 | |
dc.contributor.department | Department of Medicine |